文献速递类风湿关节炎

真实临床实践中生物及靶向合成改善病情抗风湿药治疗类风湿关节炎的短期与长期癌症风险

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

基于瑞典全国登记数据的观察性队列研究(RA患者n=69 308,匹配一般人群n=109 532,2001-2018年),评估b/tsDMARDs与首发非皮肤癌风险。TNFi总体癌症风险无增加(HR=1.0),且不随治疗起始时间、疗程或年龄变化;其他b/tsDMARDs总体风险HR为1.0-1.2,无一致升高信号,但阿巴西普治疗2-5年、老年组及部分bDMARDs与尿路癌存在统计学显著升高估计,需重复验证。

要点

  • 长期临床实践使用TNFi未增加RA患者总体癌症风险(HR=1.0)。
  • 其他b/tsDMARDs总体癌症风险HR为1.0-1.2,无一致升高信号。
  • 阿巴西普治疗2-5年、老年组及部分bDMARDs与尿路癌的信号需重复验证。

核心结论

  • 长期临床实践使用TNFi治疗RA与总体癌症风险增加无关。
  • 其他b/tsDMARDs及部位特异性风险总体令人安心,但存在需重复验证的信号。

研究设计与样本

  • 观察性全国人群基础队列研究,纳入RA患者n=69 308及匹配一般人群参照n=109 532,2001-2018年。
  • 比较TNFi(阿达木单抗、赛妥珠单抗、依那西普、戈利木单抗、英夫利西单抗)或其他b/tsDMARDs(阿巴西普、利妥昔单抗、巴瑞替尼、托法替布、托珠单抗)与未使用b/tsDMARDs的RA患者。
  • 数据来自瑞典风湿病质量登记及其他登记,链接瑞典国家癌症登记,采用Cox回归估计发病率与风险比,校正合并症及其他健康特征。

主要发现

  • RA患者中共8633例新发癌症。
  • 与未使用b/tsDMARDs的RA相比,TNFi总体癌症风险HR=1.0,且不随治疗起始时间、活性治疗持续时间或达到年龄变化。
  • 其他b/tsDMARDs总体风险HR范围为1.0至1.2,无一致升高信号。
  • 阿巴西普活性治疗2-5年、较老年组及几种bDMARDs与尿路癌之间存在统计学显著大于1的估计。

临床怎么用

  • 长期使用TNFi治疗RA时,总体癌症风险未见增加,可作为临床决策参考。
  • 使用其他b/tsDMARDs时,总体风险信号有限,但需关注阿巴西普治疗2-5年、老年患者及尿路癌相关信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the occurrence and relative risks of first-ever-incident non-cutaneous cancer overall and for 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment start, attained age, and duration of active treatment. METHODS: This is an observational nationwide and population-based cohort study of patients with RA (n = 69 308), treated with TNF inhibitors (TNFi; adalimumab, certolizumab, etanercept, golimumab, infliximab) or other b/tsDMARDs (abatacept, rituximab, baricitinib, tofacitinib and tocilizumab) compared with RA patients not treated with b/tsDMARDs, and matched general population referents (n = 109 532), 2001-2018. The study was based on prospectively collected data from the Swedish Rheumatology Quality Register and from other registers, linked to the national Swedish Cancer Register. Incidence rates and hazard ratios were estimated via Cox regression adjusted for co-morbidities and other health characteristics. RESULTS: Based on 8633 incident cancers among RA patients, the overall relative risk of cancer with TNFi [hazard ratio (HR) = 1.0] was neither increased nor did it change with time since treatment start, duration of active treatment, or attained age, when compared with b/tsDMARD-naïve RA. For other b/tsDMARDs, we noted no consistent signal of increased overall risks (HRs ranged from 1.0 to 1.2), but there were statistically significant estimates above 1 for abatacept with 2-5 years of active treatment, for older age groups, and between several of the bDMARDs and urinary tract cancer. CONCLUSION: TNFis, as used long term in clinical practice against RA, are not linked to increased risks for cancer overall. For other b/tsDMARDs, and for site-specific risks, our results are generally reassuring but contain signals that call for replication.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Huss V, Bower H, Wadström H, et al. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2022. PMID: 34324640. doi:10.1093/rheumatology/keab570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。